Equities research analysts expect Albireo Pharma Inc (NASDAQ:ALBO) to report $1.65 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Albireo Pharma’s earnings. The highest sales estimate is $3.00 million and the lowest is $850,000.00. Albireo Pharma posted sales of $11.20 million in the same quarter last year, which suggests a negative year-over-year growth rate of 85.3%. The company is expected to report its next quarterly earnings results on Thursday, May 16th.
On average, analysts expect that Albireo Pharma will report full-year sales of $9.09 million for the current year, with estimates ranging from $4.85 million to $20.00 million. For the next financial year, analysts anticipate that the company will post sales of $24.05 million, with estimates ranging from $5.34 million to $42.57 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.18). Albireo Pharma had a negative return on equity of 32.42% and a negative net margin of 361.94%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $1.94 million.
A number of research analysts have recently commented on the company. BidaskClub cut Albireo Pharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 18th. ValuEngine downgraded shares of Albireo Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Wedbush reiterated a “buy” rating and set a $69.00 price target on shares of Albireo Pharma in a research report on Friday, January 25th. Finally, HC Wainwright started coverage on shares of Albireo Pharma in a research report on Thursday, February 28th. They set a “buy” rating and a $62.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $53.40.
ALBO stock traded down $1.14 during trading hours on Friday, hitting $31.84. 3,413 shares of the stock were exchanged, compared to its average volume of 36,987. The stock has a market capitalization of $394.46 million, a price-to-earnings ratio of -8.08 and a beta of 1.72. Albireo Pharma has a 12 month low of $19.10 and a 12 month high of $37.95.
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Albireo Pharma by 11.4% during the 3rd quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock valued at $19,255,000 after purchasing an additional 59,901 shares during the last quarter. Prosight Management LP boosted its holdings in Albireo Pharma by 65.8% during the 4th quarter. Prosight Management LP now owns 270,146 shares of the biopharmaceutical company’s stock valued at $6,627,000 after acquiring an additional 107,241 shares during the period. Sectoral Asset Management Inc boosted its holdings in Albireo Pharma by 21.3% during the 4th quarter. Sectoral Asset Management Inc now owns 229,978 shares of the biopharmaceutical company’s stock valued at $5,641,000 after acquiring an additional 40,400 shares during the period. Fosun International Ltd purchased a new stake in Albireo Pharma during the 4th quarter valued at about $4,492,000. Finally, Vanguard Group Inc boosted its holdings in Albireo Pharma by 0.9% during the 3rd quarter. Vanguard Group Inc now owns 127,006 shares of the biopharmaceutical company’s stock valued at $4,186,000 after acquiring an additional 1,109 shares during the period. 66.85% of the stock is currently owned by institutional investors and hedge funds.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Recommended Story: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.